Bristol-Myers Squibb Co Stock Forecast for 2023 - 2025 - 2030

Updated on 06/04/2023

Stock Rating
2
Price Target
$83.00
Consensus
Outperform
Upside
26.41%
Analysts
13
Stock Rating
2
Upside
26.41%
Analysts
13
Price Target
$83.00

Bristol-Myers Squibb Co Stock Forecast and Price Target

If the average 2023 price target of $83.00 recently set by thridteen prominent experts for Bristol-Myers Squibb Co is met, there would be a potential upside of approximately 26.41% from the last closing price in June, 2023. The high estimate is $95.00, and the low is $60.00. If you're looking for information on Bristol-Myers Squibb Co stock, consider checking out the forecasts for comparable firms such as NasdaqGS:REGN.

$83.00

26.41% Upside

Outperform
Outperform

Bristol-Myers Squibb Co Fair Value Forecast for 2023 - 2025 - 2030

In the last two years, Bristol-Myers Squibb Co's Price has grown, rising from $47.79 to $76.53 – a growth of 60.13%. In the next year, analysts believe that Fair Value will reach $83.86 – an increase of 9.59%. By 2030, professionals predict that Bristol-Myers Squibb Co's Fair Value will decrease by 8.79%, to $69.80.

2023 Fair Value Forecast
$83.86
2024 Fair Value Forecast
$86.72
2025 Fair Value Forecast
$90.59
2026 Fair Value Forecast
$86.92
2027 Fair Value Forecast
$84.07
2028 Fair Value Forecast
$80.81
2029 Fair Value Forecast
$73.98
2030 Fair Value Forecast
$69.80
Ticker Name Consensus Stock Rating Price Buy/Sell Price Target Upside/Downside
JNJ Stock Forecast Johnson & Johnson Outperform 10
$156.97 Buy/Sell $178.79 14.99%
LLY Stock Forecast Eli Lilly & Co Outperform 14
$442.33 Buy/Sell $333.19 -9.57%
PFE Stock Forecast Pfizer Inc Outperform 3
$38.36 Buy/Sell $47.96 37.25%
MRK Stock Forecast Merck Outperform 5
$112.52 Buy/Sell $99.57 4.87%
REGN Stock Forecast Regeneron Pharmaceuticals Inc Outperform 2
$739.95 Buy/Sell $796.73 5.68%

Bristol-Myers Squibb Co Revenue Forecast for 2023 - 2025 - 2030

In the last three years, Bristol-Myers Squibb Co's Revenue has grown, rising from $26.15B to $46.16B – a growth of 76.55%. In the next year, analysts believe that Revenue will reach $48.66B – an increase of 5.42%. By 2030, professionals predict that Bristol-Myers Squibb Co's Revenue will decrease by 20.06%, to $36.90B.

2023 Rev Forecast
$48.66B
2024 Rev Forecast
$50.13B
2025 Rev Forecast
$51.08B
2026 Rev Forecast
$49.48B
2027 Rev Forecast
$47.55B
2028 Rev Forecast
$43.96B
2029 Rev Forecast
$39.19B
2030 Rev Forecast
$36.90B
Ticker Name Consensus Stock Rating Price Buy/Sell Price Target Upside/Downside
VRTX Stock Forecast Vertex Pharmaceuticals Inc Outperform 13
$333.78 Buy/Sell $363.29 -2.33%
ZTS Stock Forecast Zoetis Outperform 18
$171.88 Buy/Sell $209.70 19.27%
BAX Stock Forecast Baxter International Inc Outperform 17
$41.33 Buy/Sell $60.73 40.33%

Bristol-Myers Squibb Co Dividend per Share Forecast for 2023 - 2025 - 2030

Bristol-Myers Squibb Co's Dividend per Share has grown In the last three years, rising from $1.68 to $2.28 – a growth of 35.71%. For the following year, the 10 analysts predict that Bristol-Myers Squibb Co's Dividend per Share will drop by 1.32%, reaching $2.25. In 2030, the professionals' prediction is that BMY's Dividend per Share will decrease by 7.89%, reaching $2.10.

2023 DPS Forecast
$2.25
2024 DPS Forecast
$2.37
2025 DPS Forecast
$2.44
2026 DPS Forecast
$2.45
2027 DPS Forecast
$2.10
2028 DPS Forecast
$2.10
2029 DPS Forecast
$2.10
2030 DPS Forecast
$2.10
Ticker Name Consensus Stock Rating Price Buy/Sell Price Target Upside/Downside
ALNY Stock Forecast Alnylam Pharmaceuticals Inc Outperform 7
$193.67 Buy/Sell $244.18 29.60%
VTRS Stock Forecast Viatris Outperform 8
$9.33 Buy/Sell $13.70 44.69%
UTHR Stock Forecast United Therapeutics Outperform 12
$217.22 Buy/Sell $280.69 35.81%

Bristol-Myers Squibb Co Free Cash Flow Forecast for 2023 - 2025 - 2030

In the last three years, Bristol-Myers Squibb Co's Free Cash Flow has grown by 197613122.50%, rising from $7.37B to $14572.00T. The next year, 7 experts forecast that Bristol-Myers Squibb Co's Free Cash Flow will decrease by 100.00%, reaching $19.68B. In 2030, professionals predict that Bristol-Myers Squibb Co's Free Cash Flow will decrease by 100.00%, reaching $14.89B.

2023 FCF Forecast
$19.68B
2024 FCF Forecast
$19.61B
2025 FCF Forecast
$19.19B
2026 FCF Forecast
$19.10B
2027 FCF Forecast
$17.17B
2028 FCF Forecast
$16.36B
2029 FCF Forecast
$15.84B
2030 FCF Forecast
$14.89B
Ticker Name Consensus Stock Rating Price Buy/Sell Price Target Upside/Downside
CTLT Stock Forecast Catalent Outperform 15
$37.72 Buy/Sell $83.92 93.53%
IONS Stock Forecast Ionis Pharmaceuticals Outperform 9
$41.75 Buy/Sell $52.42 19.76%
CYTK Stock Forecast Cytokinetics Outperform 10
$38.63 Buy/Sell $62.67 55.32%

Bristol-Myers Squibb Co Net Income Forecast for 2023 - 2025 - 2030

Bristol-Myers Squibb Co's Net Income has seen impressive growth In the last three years, rising from $3.44B to $6.35B – a growth of 84.50%. In the next year, analysts believe that Net Income will reach $17.26B – an increase of 172.08%. For the next eight years, the forecast is for Net Income to grow by 109.51%.

2023 NI Forecast
$17.26B
2024 NI Forecast
$17.43B
2025 NI Forecast
$17.87B
2026 NI Forecast
$17.08B
2027 NI Forecast
$16.55B
2028 NI Forecast
$15.67B
2029 NI Forecast
$14.22B
2030 NI Forecast
$13.29B
Ticker Name Consensus Stock Rating Price Buy/Sell Price Target Upside/Downside
BCPC Stock Forecast Balchem Outperform 18
$132.82 Buy/Sell $163.67 23.48%
NEOG Stock Forecast Neogen Hold 16
$18.51 Buy/Sell $37.00 37.76%
CORT Stock Forecast Corcept Therapeutics Outperform 16
$23.26 Buy/Sell $0.00 26.83%

Bristol-Myers Squibb Co EBITDA Forecast for 2023 - 2025 - 2030

In the last three years, Bristol-Myers Squibb Co's EBITDA has grown, moving from $6.30B to $19.92B – an increase of 216.34%. In the next year, analysts predict that EBITDA will jump to $21.50B – up 7.91% from the current level. By 2030, professionals believe that Bristol-Myers Squibb Co's EBITDA will have decreased by 30.31%, falling to $13.89B.

2023 EBITDA Forecast
$21.50B
2024 EBITDA Forecast
$21.76B
2025 EBITDA Forecast
$21.84B
2026 EBITDA Forecast
$22.73B
2027 EBITDA Forecast
$19.18B
2028 EBITDA Forecast
$18.16B
2029 EBITDA Forecast
$14.60B
2030 EBITDA Forecast
$13.89B
Ticker Name Consensus Stock Rating Price Buy/Sell Price Target Upside/Downside
TGTX Stock Forecast TG Therapeutics Outperform 9
$26.56 Buy/Sell $73.38 -28.46%
INDV Stock Forecast Indivior PLC Buy 14
£165.80 Buy/Sell £3.79 -97.14%
PCRX Stock Forecast Pacira BioSciences Outperform 16
$39.09 Buy/Sell $79.67 99.54%

Bristol-Myers Squibb Co EBIT Forecast for 2023 - 2025 - 2030

In the last two years, Bristol-Myers Squibb Co's EBIT has seen an increase, rising from $4.58B to $9.82B. This represents a growth of 114.59%. Analysts predict that Bristol-Myers Squibb Co's EBIT will increase in the upcoming year, reaching $20.34B. This would represent an increase of 107.11%. Over the next eight years, experts predict that Bristol-Myers Squibb Co's EBIT will grow at a rate of 54.90%.

2023 EBIT Forecast
$20.34B
2024 EBIT Forecast
$20.77B
2025 EBIT Forecast
$21.43B
2026 EBIT Forecast
$20.31B
2027 EBIT Forecast
$19.04B
2028 EBIT Forecast
$18.30B
2029 EBIT Forecast
$16.43B
2030 EBIT Forecast
$15.21B
Ticker Name Consensus Stock Rating Price Buy/Sell Price Target Upside/Downside
AMPH Stock Forecast Amphastar Pharmaceuticals Outperform 14
$46.70 Buy/Sell $41.00 -5.78%
IRWD Stock Forecast Ironwood Pharmaceuticals Hold 14
$11.03 Buy/Sell $12.60 13.33%
SUPN Stock Forecast Supernus Pharmaceuticals Outperform 16
$33.53 Buy/Sell $35.50 1.40%

Bristol-Myers Squibb Co EPS Price Prediction Forecast for 2023 - 2025 - 2030

In the last two years, Bristol-Myers Squibb Co's EPS has grown, rising from $4.69 to $7.51 – a growth of 60.13%. In the next year, analysts believe that EPS will reach $8.23 – an increase of 9.59%. By 2030, professionals predict that Bristol-Myers Squibb Co's EPS will decrease by 8.79%, to $6.85.

2023 EPS Forecast
$8.23
2024 EPS Forecast
$8.51
2025 EPS Forecast
$8.89
2026 EPS Forecast
$8.53
2027 EPS Forecast
$8.25
2028 EPS Forecast
$7.93
2029 EPS Forecast
$7.26
2030 EPS Forecast
$6.85
Ticker Name Consensus Stock Rating Price Buy/Sell Price Target Upside/Downside
LGND Stock Forecast Ligand Pharmaceuticals Outperform 14
$72.13 Buy/Sell $195.43 119.74%
MDGL Stock Forecast Madrigal Pharmaceuticals Outperform 4
$259.94 Buy/Sell $170.08 -32.68%
USNA Stock Forecast USANA Health Sciences Hold 14
$63.54 Buy/Sell $104.00 -10.29%